Developed on the basis of germline BRCA1/2 mutations and their role in tumor pathology, poly (ADP-ribose) polymerase (PARP) inhibitors are a further therapy option for patients with advanced HER2-negative disease, including both triple-negative and hormone-receptor-positive BC patients, who make up about 50% of all aBC patients [95]. This evidence concerns the gene ERBB2 and breast cancer.